BenevolentAI has announced that a new heart failure target has been added to its discovery portfolio by AstraZeneca through their ongoing collaboration. This novel heart failure target was identified using BenevolentAI's AI-driven drug discovery platform and subsequently validated experimentally by AstraZeneca.
The partnership was initiated in 2019 for the exchange of technology and biomedical knowledge from BenevolentAI and scientific expertise from AstraZeneca for effective target identification. The studies initially focused on idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) and have expanded to include heart failure and Systemic Lupus Erythematosus (SLE).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.